Menu Search
Equities

Certara Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
700:HAM

Certara Inc

Actions
  • Price (EUR)6.20
  • Today's Change-0.178 / -2.79%
  • Shares traded1.00k
  • 1 Year change-52.24%
  • Beta1.5064
Data delayed at least 15 minutes, as of Feb 06 2026 16:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

  • Revenue in USD (TTM)415.55m
  • Net income in USD10.88m
  • Incorporated2017
  • Employees1.49k
  • Location
    Certara Inc4 Radnor Corporate Center, Suite 350RADNOR 19087United StatesUSA
  • Phone+1 (415) 237-8272
  • Fax+1 (302) 636-5454
  • Websitehttps://www.certara.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.